Stuart Hogarth
Stuart Hogarth
Lecturer, Department of Sociology, University of Cambridge
Verified email at
Cited by
Cited by
The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues
S Hogarth, G Javitt, D Melzer
Annu. Rev. Genomics Hum. Genet. 9, 161-182, 2008
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities
F Becker, CG Van El, D Ibarreta, E Zika, S Hogarth, P Borry, ...
European journal of human genetics 19 (1), S6-S44, 2011
Reflections on the cost of" low-cost" whole genome sequencing: framing the health policy debate
T Caulfield, J Evans, A McGuire, C McCabe, T Bubela, R Cook-Deegan, ...
PLoS biology 11 (11), e1001699, 2013
Genetic tests for common diseases: new insights, old concerns
D Melzer, S Hogarth, K Liddell, T Ling, S Sanderson, RL Zimmern
Bmj 336 (7644), 590-593, 2008
Negotiating the boundary between medicine and consumer culture: Online marketing of nutrigenetic tests
PM Saukko, M Reed, N Britten, S Hogarth
Social science & medicine 70 (5), 744-753, 2010
Valley of the unicorns: consumer genomics, venture capital and digital disruption
S Hogarth
New Genetics and Society 36 (3), 250-272, 2017
A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA
S Hogarth, MM Hopkins, V Rodriguez
Sociology of health & illness 34 (2), 234-250, 2012
A market in the making: the past, present and future of direct-to-consumer genomics
S Hogarth, P Saukko
New Genetics and Society 36 (3), 197-208, 2017
The future of direct-to-consumer clinical genetic tests
FW Frueh, HT Greely, RC Green, S Hogarth, S Siegel
Nature Reviews Genetics 12 (7), 511-515, 2011
Half a century of Wilson & Jungner: reflections on the governance of population screening
S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ...
Wellcome Open Research 5, 2020
Regenerative medicine in Europe: global competition and innovation governance
S Hogarth, B Salter
Regenerative Medicine 5 (6), 971-985, 2010
Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
S Hogarth
Social Science & Medicine 131, 255-262, 2015
Closing the gaps: enhancing the regulation of genetic tests using responsive regulation
S Hogarth, K Liddell, T Ling, S Sanderson
Food & Drug LJ 62, 831, 2007
Myths, misconceptions and myopia: searching for clarity in the debate about the regulation of consumer genetics
S Hogarth
Public Health Genomics 13 (5), 322-326, 2010
The IVD directive and genetic testing problems and proposals
S Hogarth, D Melzer
A briefing presented to the 20th Meeting of Competent Authorities. Lisbon, 2007
The golden narrative in British medicine: Dialogue and discourse in clinical practice
S Hogarth, L Marks
Narrative-Based Medicine, 1998
Health Canada needs to act on laboratory-developed diagnostics
K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth
CMAJ 191 (39), E1067-E1069, 2019
Regulatory experiments and transnational networks: the governance of pharmacogenomics in Europe and the United States
S Hogarth
Innovation: The European Journal of Social Science Research 25 (4), 441-460, 2012
Biomarker patents for diagnostics: problem or solution?
MM Hopkins, S Hogarth
Nature biotechnology 30 (6), 498-500, 2012
Personalized medicine: renewing the social science research agenda
S Hogarth, M Hopkins, A Faulkner
Personalized Medicine 9 (2), 121-126, 2012
The system can't perform the operation now. Try again later.
Articles 1–20